Skip to main content

Immunohistochemistry Validation: Past, Present and Future

Validation procedures are part of the regulatory process in a laboratory setting.  Understanding the basic principles and reasons for validation is important for laboratory compliance of regulations and eventually for patient diagnosis and treatments of diseases.  A discussion of current trends and changes with the latest CAP checklist will be reviewed and future direction of where IHC validation may end up will be discussed.

Learning Objectives

  1. Understanding of the basic principles and reasons for the validation process.
  2. Describe historical perspective of past IHC validation requirements.
  3. Discuss current trends and changes in validation requirements (CAP latest checklist).
  4. Examine the future direction of where the IHC validation process may end up.

About the presenter

Philip Ferguson , M.D.

Dr. Philip Ferguson is in a private practice located in Arkansas. He has a diverse training background that includes an undergraduate degree in mechanical engineering, post-graduate training in internal medicine, and board certifications in anatomic pathology, clinical pathology, and hematopathology. His professional interests center around educational resource development for pathologists and trainees, and use of immunohisochemistry and molecular diagnostics in surgical pathology. Dr. Ferguson launched one of the first widespread internet educational tools for pathology residents to prepare for their board examination, PathMD (www.PathMD.com), which is now the Leica tool PathLead. Dr. Ferguson also serves as a state commissioner for the College of American Pathologists' Accreditation and Laboratory Improvement Program and is also member of the Global Advisory Board for Leica Biosystems. Dr. Ferguson has published several publication of late including ‘The Effect of Decalcification Solutions on Kappa and Lambda In-Situ Hybridization,’ as well as ‘Effects of Decalcification on Immunohistochemistry Comparing: Immunocal®, Formical2000®, and EDTA Stat®.’

Die Inhalte des Knowledge Pathway von Leica Biosystems unterliegen den Nutzungsbedingungen der Website von Leica Biosystems, die hier eingesehen werden können: Rechtlicher Hinweis. Der Inhalt, einschließlich der Webinare, Schulungspräsentationen und ähnlicher Materialien, soll allgemeine Informationen zu bestimmten Themen liefern, die für medizinische Fachkräfte von Interesse sind. Er soll explizit nicht der medizinischen, behördlichen oder rechtlichen Beratung dienen und kann diese auch nicht ersetzen. Die Ansichten und Meinungen, die in Inhalten Dritter zum Ausdruck gebracht werden, spiegeln die persönlichen Auffassungen der Sprecher/Autoren wider und decken sich nicht notwendigerweise mit denen von Leica Biosystems, seinen Mitarbeitern oder Vertretern. Jegliche in den Inhalten enthaltene Links, die auf Quellen oder Inhalte Dritter verweisen, werden lediglich aus Gründen Ihrer Annehmlichkeit zur Verfügung gestellt.

Vor dem Gebrauch sollten die Produktinformationen, Beilagen und Bedienungsanleitungen der jeweiligen Medikamente und Geräte konsultiert werden.

Copyright © 2024 Leica Biosystems division of Leica Microsystems, Inc. and its Leica Biosystems affiliates. All rights reserved. LEICA and the Leica Logo are registered trademarks of Leica Microsystems IR GmbH.